T. Rowe Price Associates
ONCE

T. Rowe Price Associates’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

T. Rowe Price Associates’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-307,837
Closed -$29.9M – 2580
2019
Q3 		$29.9M Sell
307,837
-386,859
-56% -$38.7M ﹤0.01% 1031
2019
Q2 		$71.1M Buy
694,696
+2,381
+0.3% +$257K 0.01% 761
2019
Q1 		$78.8M Sell
692,315
-1,278,451
-65% -$94M 0.01% 704
2018
Q4 		$77.1M Sell
1,970,766
-577,184
-23% -$25M 0.01% 675
2018
Q3 		$139M Sell
2,547,950
-485,182
-16% -$33.2M 0.02% 577
2018
Q2 		$251M Sell
3,033,132
-876,736
-22% -$67.7M 0.04% 411
2018
Q1 		$260M Sell
3,909,868
-217,093
-5% -$12.5M 0.04% 399
2017
Q4 		$212M Buy
4,126,961
+304,002
+8% +$21.8M 0.03% 448
2017
Q3 		$341M Buy
3,822,959
+650,561
+21% +$49.4M 0.06% 337
2017
Q2 		$190M Sell
3,172,398
-200,387
-6% -$11.2M 0.03% 452
2017
Q1 		$180M Buy
3,372,785
+331,069
+11% +$19.7M 0.03% 449
2016
Q4 		$152M Buy
3,041,716
+135,220
+5% +$7.24M 0.03% 480
2016
Q3 		$175M Buy
2,906,496
+248,309
+9% +$14.3M 0.04% 461
2016
Q2 		$136M Buy
2,658,187
+145,580
+6% +$6.22M 0.03% 488
2016
Q1 		$74.1M Buy
2,512,607
+459,679
+22% +$14.5M 0.02% 645
2015
Q4 		$93M Buy
2,052,928
+795,520
+63% +$41.7M 0.02% 577
2015
Q3 		$52.5M Buy
1,257,408
+126,112
+11% +$6.58M 0.01% 758
2015
Q2 		$65.9M Sell
1,131,296
-73,230
-6% -$4.84M 0.01% 744
2015
Q1 		$90.4M Buy
+1,204,526
New +$69.4M 0.02% 649

T. Rowe Price Associates's ONCE Position: Q4 2019 in Review

T. Rowe Price Associates sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 307,837 shares — an estimated $29.9M sold.

T. Rowe Price Associates first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $341M in Q3 2017. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • T. Rowe Price Associates reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • T. Rowe Price Associates sold 307,837 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $29.9M.
  • T. Rowe Price Associates first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
  • T. Rowe Price Associates's Spark Therapeutics, Inc. Common Stock position peaked at $341M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on T. Rowe Price Associates's 13F filing for Q4 2019, filed 14 Feb 2020.